Idasanutlin
- Generic Name
- Idasanutlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H29Cl2F2N3O4
- CAS Number
- 1229705-06-9
- Unique Ingredient Identifier
- QSQ883V35U
- Background
Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02828930
- Locations
- ðŸ‡ðŸ‡º
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT02670044
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
🇫🇷Institut Paoli Calmettes, Marseille, France
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT02633059
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT02624986
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇩🇪Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 447
- Registration Number
- NCT02545283
- Locations
- 🇫🇷
Hopital Claude Huriez; Hematologie, Lille, France
🇫🇷Institut J Paoli I Calmettes; Onco Hematologie 2, Marseille, France
🇫🇷Hopital Saint Louis; Oncologie Medicale, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.